Artelo Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

• Artelo Biosciences Inc ARTL.OQ reported a quarterly adjusted loss of 35 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -83 cents. The mean expectation of four analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -79 cents to -19 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Artelo Biosciences Inc's reported EPS for the quarter was a loss of 35 cents​.

• The company reported a quarterly loss of $1.13 million.

• Artelo Biosciences Inc shares had risen by 10.4% this quarter and lost 11.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 15.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Artelo Biosciences Inc is 5.50

This summary was machine generated from LSEG data November 12 at 03:47 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)